Entry into a Material Definitive Agreement

Filing Overview

Form 8-K filed June 16, 2023 by Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP; COEPW), reporting the closing of a registered public offering. The request metadata identifies “Z Squared Inc.,” but the filing names Coeptis Therapeutics Holdings, Inc. as the registrant.

Material Transaction and Key Financial Metrics

  • The offering closed on June 16, 2023 under an underwriting agreement with Ladenburg Thalmann & Co. Inc.
  • The company issued and sold 2,150,000 common shares and 1,350,000 pre-funded warrants.
  • The offering also included 3,062,500 Series A warrants and 3,062,500 Series B warrants, each with a $1.65 exercise price and a five-year exercise period beginning six months after issuance.
  • Pre-funded warrants have an exercise price of $0.0001 per share and were offered to purchasers subject to beneficial ownership limitations.
  • Gross proceeds were approximately $3.5 million, before underwriting discounts, commissions, and other estimated offering expenses, and excluding any warrant exercises.
  • The filing does not provide a clear amount for net proceeds, cash balance, liquidity, revenue, profit, cash flow, margins, or debt.

Changes, Terms, and Restrictions

  • The securities contain fixed pricing and do not include variable pricing, reset provisions, or price-based anti-dilution features.
  • The company, directors, and executive officers agreed to a 75-day lock-up period, subject to limited exceptions.
  • Until the first anniversary of the closing, the company is generally prohibited from entering into variable-rate transactions, with an exception permitting an at-the-market offering facility after the 90th day following closing.
  • The company entered into a warrant agent agreement with Continental Stock Transfer & Trust Company.

Outlook, Risks, and Unusual Items

The filing does not provide operating guidance or a broader business outlook. Key risks include dilution from the shares, pre-funded warrants, and potential exercise of the Series A and Series B warrants; the company’s ability to deploy the approximately $3.5 million of gross proceeds; and restrictions on future financing transactions. The filing also states that the company agreed to indemnify the underwriter against certain liabilities, including liabilities under the Securities Act.

Investor Verification Points

  • Verify the final net proceeds after underwriting discounts, commissions, and offering expenses.
  • Review the underwriting agreement and warrant forms for complete terms, including exercise mechanics and adjustment provisions.
  • Assess the potential dilution from all outstanding shares and warrants.
  • Confirm the company’s post-offering cash balance, liquidity runway, and planned use of proceeds in subsequent filings.
  • Reconcile the registrant’s identity, because the supplied metadata references Z Squared Inc. while the filing identifies Coeptis Therapeutics Holdings, Inc.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.